Document 1190
 DOCN  M94A1190
 TI    AIDS neutropenia management with colonies stimulating factors (GMCSF and
       GCSF).
 DT    9412
 AU    Alvarado-Diez R; Feregrino-Goyos M; Eid-Lidt G; Gallegos-Perez H;
       Clinica ISI de Norteamerica, Mexico, DF.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):189 (abstract no. PB0768). Unique
       Identifier : AIDSLINE ICA10/94371385
 AB    OBJECTIVES: Evaluate the benefits of the correction of leukopenia less
       than 1500 and neutropenia less than 500 with Stimulating Factors of
       Colonies (GCSF and GMCSF) in the evolution and prognosis of HIV patients
       in stages III and IV of CDCwith severe opportunistic infections or those
       who require chemotherapy treatment for Lymphoma and S.K. or treatment
       with ganciclovir for CMV, or urgent surgery. Evaluate if they receive
       some benefit from the combination of both factors simultaneously and
       evaluate if the levels of antigenes p 24 increase or decrease during
       long range therapy. METHODS: 75 HIV neutropennic (-500) patients were
       randomized in three groups: GROUP 1 of 50 - patients received 300 to 900
       mcg sc of GCSF every 24 hrs, spacing the application by the response of
       the leukopenia every 48, 72 or 96 hrs. during a minimum period of 1
       month up to 16 months. Group II was formed by 20 patients who received
       300 to 900 mcg sc of GMCSF in period of 24, 48, 72 or 96 hrs as the
       evolution of neutropennia indicated. Group III formed by 5 patients with
       severe neutropenia secondary to QT received the combination of GCSF and
       GMCSF for - short periods of less than 30 days. Diagnosis, age, and CD4
       was studied. Statistical with T Students and chi 2. RESULTS: Patient's
       age was 37.1(groupI), 33.7(groupII, and 35 (groupIII (pNS). CD4 counts
       were 41.8, 69.08, and 52 in each group (pNS). Diagnosis were treatment
       with ganciclovir for CMV in 25, 10 and 0, Lymphoma or S.K. chemotherapy
       in 10, 5 and 5 resp.; opportunistic infections in 7, 2, and 0;
       toxoplasmosis in 4, 1, and 0; septic surgery in 4, 1, and 0 and 1
       patient with varicella zoster in group I. Correction of leukopenia was
       observed 72 hrs after application of GCSF and 120 hrs after GMCSF but
       similar responses after 7 days was observed. No modification of levels
       of p24 antigeno. The combination of both decresed the lapsus of postQT
       neutropenia.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Adult  AIDS-Related
       Opportunistic Infections/THERAPY  Comparative Study  Cytomegalovirus
       Infections/DRUG THERAPY  Drug Therapy, Combination
       Ganciclovir/THERAPEUTIC USE  Granulocyte Colony-Stimulating
       Factor/*THERAPEUTIC USE  Granulocyte-Macrophage Colony-Stimulating
       Factor/*THERAPEUTIC USE  Human  Leukocyte Count
       Neutropenia/ETIOLOGY/*THERAPY  Toxoplasmosis/THERAPY  T4 Lymphocytes
       CLINICAL TRIAL  MEETING ABSTRACT  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).